Kaizhe Wang

Dr. Kaizhe Wang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2024 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
ZLZhixiao Liu
Zhixiao Liu
YLYingying Liu
Yingying Liu
YLYu Li
Yu Li
SXSha Xu
Sha Xu
YWYang Wang
Yang Wang
YWYue Wang
Yue Wang
Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) have garnered extensive attention as natural product-based nanomedicines and potential drug delivery vehicles. However, the specific mechanism for regulating MSC-EVs secretion and delivery remains unclear. Here, we demonstrate that extracellular matrix (ECM) stiffness regulates the secretion and delivery of EVs by affecting MSCs' cargo sorting mechanically. Using multi-omics analysis, we found that a decrease in ECM stiffness impeded the sorting of vesicular transport-related proteins and autophagy-related lipids into MSC-EVs, impairing their secretion and subsequent uptake by macrophages. Hence, MSC-EVs with different secretion and uptake behaviors can be produced by changing the stiffness of culture substrates. This study provides new insights into MSC-EV biology and establishes a connection between MSC-EV behaviors and ECM from a biophysical perspective, providing a basis for the rational design of biomedical materials. Graphical Abstract

10 December 2023 in Advanced Materials
Verified
Journal Article
Closed access
XYXuxiang Yao
Xuxiang Yao
DHDongdong He
Dongdong He
PWPengyao Wei
Pengyao Wei
ZNZitong Niu
Zitong Niu
HCHao Chen
Hao Chen
KWKaizhe Wang
Kaizhe Wang

18 December 2024 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
SLSaiyun Lou
Saiyun Lou
WHWei Hu
Wei Hu
PWPengyao Wei
Pengyao Wei
DHDongdong He
Dongdong He
PFPan Fu
Pan Fu
KWKaizhe Wang
Kaizhe Wang

26 March 2024 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
TKTong Kong
Tong Kong
YQYang Qu
Yang Qu
TZTaowa Zhao
Taowa Zhao
ZNZitong Niu
Zitong Niu
XLXiuyi Lv
Xiuyi Lv
KWKerong Wu
Kerong Wu
Background: Bladder cancer (BC) is a very common urinary tract malignancy that has a high incidence and lethality. In this study, we identified BC biomarkers and described a new noninvasive detection method using serum and urine samples for the early detection of BC. Methods: Serum and urine samples were retrospectively collected from patients with BC (n = 99) and healthy controls (HC) (n = 50), and the expression levels of 92 inflammation-related proteins were examined via the proximity extension analysis (PEA) technique. Differential protein expression was then evaluated by univariate analysis (p < 0.05). The expression of the selected potential marker was further verified in BC and adjacent tissues by immunohistochemistry (IHC) and single-cell sequencing. A model was constructed to differentiate BC from HC by LASSO regression and compared to the detection capability of FISH. Results: The univariate analysis revealed significant differences in the expression levels of 40 proteins in the serum (p < 0.05) and 17 proteins in the urine (p < 0.05) between BC patients and HC. Six proteins (AREG, RET, WFDC2, FGFBP1, ESM-1, and PVRL4) were selected as potential BC biomarkers, and their expression was evaluated at the protein and transcriptome levels by IHC and single-cell sequencing, respectively. A diagnostic model (a signature) consisting of 14 protein markers (11 in serum and three in urine) was also established using LASSO regression to distinguish between BC patients and HC (area under the curve = 0.91, PPV = 0.91, sensitivity = 0.87, and specificity = 0.82). Our model showed better diagnostic efficacy than FISH, especially for early-stage, small, and low-grade BC. Conclusion: Using the PEA method, we identified a panel of potential protein markers in the serum and urine of BC patients. These proteins are associated with the development of BC. A total of 14 of these proteins can be used to detect early-stage, small, low-grade BC. Thus, these markers are promising for clinical translation to improve the prognosis of BC patients. Graphical

30 May 2024 in JACS Au
Verified
Journal Article
Open access
HCHao Chen
Hao Chen
QDQiaojiao Ding
Qiaojiao Ding
LLLin Li
Lin Li
PWPengyao Wei
Pengyao Wei
ZNZitong Niu
Zitong Niu
JZJianping Zheng
Jianping Zheng
Extracellular vesicles (EVs) are naturally occurring vesicles secreted by cells that can transport cargo between cells, making them promising bioactive nanomaterials. However, due to the complex and heterogeneous biological characteristics, a method for robust EV manipulation and efficient EV delivery is still lacking. Here, we developed a novel class of extracellular vesicle spherical nucleic acid (EV-SNA) nanostructures with scalability, programmability, and efficient cellular delivery. EV-SNA was constructed through the simple hydrophobic coassembly of natural EVs with cholesterol-modified oligonucleotides and can be stable for 1 month at room temperature. Based on programmable nucleic acid shells, EV-SNA can respond to AND logic gates to achieve vesicle assembly manipulation. Importantly, EV-SNA can be constructed from a wide range of biological sources EV, enhancing cellular delivery capability by nearly 10-20 times. Compared to artificial liposomal SNA, endogenous EV-SNA exhibited better biocompatibility and more effective delivery of antisense oligonucleotides in hard-to-transfect primary stem cells. Additionally, EV-SNA can deliver functional EVs for immune regulation. As a novel material form, EV-SNA may provide a modular and programmable framework paradigm for EV-based applications in drug delivery, disease treatment, nanovaccines, and other fields.

8 February 2025 in Analytical Chemistry
Verified
Journal Article
Closed access
QSQingwei Song
Qingwei Song
ZLZixuan Liao
Zixuan Liao
LZLin Zheng
Lin Zheng
PFPan Fu
Pan Fu
SQSihua Qian
Sihua Qian
YWYuhui Wang
Yuhui Wang